参考文献/References:
[1] Melo M,Gaspar da Rocha A,Batista R,et al.TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease[J].J Clin Endocrinol Metab,2017,102(6):1898-1907.DOI:10.1210/jc.2016-2785.
[2] Luo D,Zhan S,Xia W,et al.Proteomics study of serum exosomes from papillary thyroid cancer patients[J].Endocr Relat Cancer,2018,25(10):879-891.DOI:10.1530/ERC-17-0547.
[3] Nicholson JK, Connelly J, Lindon JC,et al.Metabonomics: a platform for studying drug toxicity and gene function[J].Nat Rev Drug Discov,2002,1(2):153-161.DOI: 10.1038/nrd728.
[4] Deja S,Dawiskiba T,Balcerzak W,et al.Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions[J].PLoS One,2013,8(12):e84637. DOI:10.1371/journal.pone.0084637.
[5] Brennan L.NMR-based metabolomics: from sample preparation to applications in nutrition research[J].Prog Nucl Magn Reson Spectrosc,2014,83:42-49.DOI:10.1016/j.pnmrs.2014.09.001.
[6] 赵祯,马宇,沈国华,等.代谢组学在甲状腺疾病中的应用 [J].中华核医学与分子影像杂志,2017,37(1):49-52.DOI:10.3760/cma.j.issn.2095-2848.2017.01.014.
[7] O'Connell TM.Recent advances in metabolomics in oncology[J].Bioanalysis,2012,4(4):431-451.DOI:10.4155/bio.11.326.
[8] Griffin JL,Walker L,Shore RF,et al.High-resolution magic angle spinning 1H-NMR spectroscopy studies on the renal biochemistry in the bank vole(Clethrionomys glareolus)and the effects of arsenic(As3+)toxicity[J].Xenobiotica,2001,31(6):377-385.DOI:10.1080/00498250110055938.
[9] Drexler DM,Reily MD,Shipkova PA.Advances in mass spectrometry applied to pharmaceutical metabolomics[J].Anal Bioanal Chem,2011,399(8):2645-2653.DOI:10.1007/s00216-010-4370-8.
[10] Zhang A,Sun H,Wang P,et al.Modern analytical techniques in metabolomics analysis[J].Analyst,2012,137(2):293-300.DOI:10.1039/c1an15605e.
[11] Fuhrer T,Zamboni N.High-throughput discovery metabolomics[J].Curr Opin Biotechnol,2015,31:73-78.DOI:10.1016/j.copbio.2014.08.006.
[12] Taylor J,King RD,Altmann T,et al.Application of metabolomics to plant genotype discrimination using statistics and machine learning[J].Bioinformatics,2002,18(Suppl 2):S241-S248.
[13] Dunn WB,Bailey NJ,Johnson HE.Measuring the metabolome: current analytical technologies[J].Analyst,2005,130(5):606-625.DOI:10.1039/b418288j.
[14] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)[J].中华核医学与分子影像杂志,2014,34(4):264-278.DOI:10.3760/cma.j.issn.2095-2848.2014.04.002.
[15] Yao Z,Yin P,Su D,et al.Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter[J].Mol Biosyst,2011,7(9):2608-2614.DOI:10.1039/c1mb05029j.
[16] 叶艳,赵树君,李永梅,等.碘摄入量对TPC-1甲状腺乳头状癌原位裸鼠模型的影响[J]. 中华内分泌代谢杂志,2014,30(7):558-561.DOI:10.3760/cma.j.issn.1000-6699.2014.07.004.
[17] Miccoli P,Torregrossa L,Shintu L,et al.Metabolomics approach to thyroid nodules: a high-resolution magic-angle spinning nuclear magnetic resonance-based study[J].Surgery,2012,152(6):1118-1124.DOI:10.1016/j.surg.2012.08.037.
[18] Shang X,Zhong X,Tian X.Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy[J].Tumour Biol,2016,37(8):11163-11175.DOI:10.1007/s13277-016-4996-z.
[19] Zhao WX,Wang B,Zhang LY,et al.Analysis on the metabolite composition of serum samples from patients with papillary thyroid carcinoma using nuclear magnetic resonance[J].Int J Clin Exp Med,2015,8(10):18013-18022.
[20] Li Y,Chen M,Liu C,et al.Metabolic changes associated with papillary thyroid carcinoma: a nuclear magnetic resonance-based metabolomics study[J].Int J Mol Med,2018,41(5):3006-3014.DOI:10.3892/ijmm.2018.3494.
[21] Jordan KW,Adkins CB,Cheng LL,et al.Application of magnetic-resonance-spectroscopy- based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma[J].Acta Cytol,2011,55(6):584-589.DOI:10.1159/000333271.
[22] Torregrossa L,Shintu L,Nambiath Chandran J,et al.Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study[J].J Proteome Res,2012,11(6):3317-3325.DOI:10.1021/pr300105e.
[23] Ryoo I,Kwon H,Kim SC,et al.Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: potential application for the preoperative diagnosis of thyroid cancer[J].Sci Rep,2016,6:30075.DOI:10.1038/srep30075.
[24] 郑雯洁,徐雅男,周秦毅,等.女性甲状腺乳头状癌代谢组学特征及其与肿瘤大小、淋巴结转移的关系[J].中华耳鼻咽喉头颈外科杂志,2016,51(2):105-111.DOI:10.3760/cma.j.issn.1673-0860.2016.02.007.
[25] Seo JW,Han K,Lee J,et al.Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma[J].PLoS One,2018,13(3):e0193883. DOI:10.1371/journal.pone.0193883.
[26] Xu Y,Zheng X,Qiu Y,et al.Distinct metabolomic profiles of papillary thyroid carcinoma and benign thyroid adenoma[J].J Proteome Res,2015,14(8):3315-3321.DOI:10.1021/acs.jproteome.5b00351.
[27] 阿布都沙拉木·阿布力.甲状腺乳头状癌和结节性甲状腺肿患者血浆代谢组学研究[D].新疆医科大学, 2014.
[28] 中华医学会核医学分会.131I治疗格雷夫斯甲亢指南(2013版)[J].中华核医学与分子影像杂志,2013, 33(2):83-95. DOI:10.3760/cma.j.issn.2095-2848.
[29] Piras C,Arisci N,Poddighe S,et al.Metabolomic profile in hyperthyroid patients before and after antithyroid drug treatment: correlation with thyroid hormone and TSH concentration[J].Int J Biochem Cell Biol,2017,93:119-128.DOI:10.1016/j.biocel.2017.07.024.
[30] Chng CL,Lim AY,Tan HC,et al.Physiological and metabolic changes during the transition from hyperthyroidism to euthyroidism in Graves' disease[J].Thyroid,2016,26(10):1422-1430.DOI:10.1089/thy.2015.0602.
[31] Al-Majdoub M,Lantz M,Spégel P.Treatment of swedish patients with Graves' hyperthyroidism is associated with changes in acylcarnitine levels[J].Thyroid,2017,27(9):1109-1117.DOI:10.1089/thy.2017.0218.
[32] Wu S,Tan G,Dong X,et al.Metabolic profiling provides a system understanding of hypothyroidism in rats and its application[J].PLoS One,2013,8(2):e55599.DOI:10.1371/journal.pone.0055599.
[33] Yao X,Sa R,Ye C,et al.Effects of thyroid hormone status on metabolic pathways of arachidonic acid in mice and humans: a targeted metabolomic approach[J].Prostaglandins Other Lipid Mediat,2015,118-119:11-18.DOI:10.1016/j.prostaglandins.2015.03.005.
[34] Chen YK,Lin CL,Cheng FT,et al.Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study[J].Br J Cancer,2013,109(9):2496-2501.DOI:10.1038/bjc.2013.597.
[35] Zhang Y,Dai J,Wu T,et al.The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma[J].J Cancer Res Clin Oncol,2014,140(6):1021-1026.DOI:10.1007/s00432-014-1629-z.
[36] Liang J,Zeng W,Fang F,et al.Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients[J].Acta Otorhinolaryngol Ital,2017,37(5):393-400.DOI:10.14639/0392-100X-1709.
[37] Marotta V,Sciammarella C,Chiofalo MG,et al.Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer[J].Endocr Relat Cancer,2017,24(9):485-493.DOI:10.1530/ERC-17-0085.
[38] Pagni F, De Sio G, Garancini M,et al. Proteomics in thyroid cytopathology: relevance of MALDI-imaging in distinguishing malignant from benign lesions[J].Proteomics,2016,16(11-12):1775-1784. DOI:10.1002/pmic.201500448.
相似文献/References:
[1]张蓉,俞立波,李连喜.组蛋白修饰与甲状腺癌[J].国际内分泌代谢杂志,2014,(05):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
Zhang Rong,Yu Libo,Li Lianxi..Histone modification and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2014,(03):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
[2]李兴佳,徐书杭,刘超.雌激素及其受体与甲状腺癌的关系[J].国际内分泌代谢杂志,2016,36(04):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
Li Xingjia,Xu Shuhang,Liu Chao.Relationship between estrogen, its receptors and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2016,36(03):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(03):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]郑仁东,刘超.STAT3与甲状腺肿瘤[J].国际内分泌代谢杂志,2017,37(05):345.
Zheng Rendong,Liu Chao..STAT3 and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2017,37(03):345.
[5]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(03):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[6]曹星月 武晓泓.基因拷贝数异常在甲状腺癌诊断和预后判断中的
应用进展[J].国际内分泌代谢杂志,2019,39(01):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
Cao Xingyue,Wu Xiaohong.Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(03):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
[7]张会峰 胡天赤 陈学勤 叶向荣 刘超.丙型肝炎病毒感染与自身免疫性甲状腺疾病
及甲状腺癌风险[J].国际内分泌代谢杂志,2019,39(02):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
Zhang Huifeng,Hu Tianchi,Chen Xueqin,et al.Relationship between hepatitis C virus infection and the risk of autoimmune thyroid diseases and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(03):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
[8]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(03):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[9]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(03):469.[doi:10.3760/cma.j.cn121383-20210926-09075]